Jazz Pharmaceuticals plc Variable Lease, Cost
Jazz Pharmaceuticals plc (JAZZ) reported Variable Lease, Cost of $242.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:VariableLeaseCost · last filed 2026-02-24
- Jazz Pharmaceuticals plc variable lease, cost for the quarter ending 2021-03-31 was $1.00K, a 0.00% change year-over-year.
- Jazz Pharmaceuticals plc variable lease, cost for the quarter ending 2020-12-31 was $1.00K, a 0.00% change year-over-year.
- Jazz Pharmaceuticals plc variable lease, cost for the quarter ending 2020-09-30 was $1.00K.
- Jazz Pharmaceuticals plc variable lease, cost for the quarter ending 2020-06-30 was $0.00, a 100.00% decline year-over-year.
- Jazz Pharmaceuticals plc variable lease, cost for fiscal 2025 was $242.00K, a 69.33% decline from fiscal 2024.
- Jazz Pharmaceuticals plc variable lease, cost for fiscal 2024 was $789.00K, a 874.07% increase from fiscal 2023.
- Jazz Pharmaceuticals plc variable lease, cost for fiscal 2023 was $81.00K, a 1520.00% increase from fiscal 2022.
- Jazz Pharmaceuticals plc variable lease, cost for fiscal 2022 was $5.00K, a 50.00% decline from fiscal 2021.
| Period end | Variable Lease, Cost 3 month | Variable Lease, Cost 6 month | Variable Lease, Cost 9 month | Variable Lease, Cost 12 month |
|---|---|---|---|---|
| 2025-12-31 | $242.00K 10-K · filed 2026-02-24 | |||
| 2024-12-31 | $789.00K 10-K · filed 2026-02-24 | |||
| 2023-12-31 | $81.00K 10-K · filed 2026-02-24 | |||
| 2022-12-31 | $5.00K 10-K · filed 2025-02-26 | |||
| 2021-12-31 | $10.00K 10-K · filed 2024-02-28 | |||
| 2021-03-31 | $1.00K 10-Q · filed 2021-05-04 | $2.00K derived: sum of 2 quarters · filed 2023-03-01 | $3.00K derived: sum of 3 quarters · filed 2023-03-01 | $3.00K derived: sum of 4 quarters · filed 2023-03-01 |
| 2020-12-31 | $1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $2.00K derived: sum of 2 quarters · filed 2023-03-01 | $2.00K derived: sum of 3 quarters · filed 2023-03-01 | $3.00K 10-K · filed 2023-03-01 |
| 2020-09-30 | $1.00K 10-Q · filed 2020-11-02 | $1.00K derived: sum of 2 quarters · filed 2020-11-02 | $2.00K 10-Q · filed 2020-11-02 | $3.00K derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | $0.00 10-Q · filed 2020-08-04 | $1.00K 10-Q · filed 2020-08-04 | $2.00K derived: sum of 3 quarters · filed 2022-03-01 | $2.00K derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | $1.00K 10-Q · filed 2021-05-04 | $2.00K derived: sum of 2 quarters · filed 2022-03-01 | $2.00K derived: sum of 3 quarters · filed 2022-03-01 | $3.00K derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | $1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $1.00K derived: sum of 2 quarters · filed 2022-03-01 | $2.00K derived: sum of 3 quarters · filed 2022-03-01 | $5.00K 10-K · filed 2022-03-01 |
| 2019-09-30 | $0.00 10-Q · filed 2020-11-02 | $1.00K derived: sum of 2 quarters · filed 2020-11-02 | $4.00K 10-Q · filed 2020-11-02 | |
| 2019-06-30 | $1.00K 10-Q · filed 2020-08-04 | $4.00K 10-Q · filed 2020-08-04 | ||
| 2019-03-31 | $3.00K 10-Q · filed 2020-05-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |